BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Topics » Science, BioWorld MedTech

Science, BioWorld MedTech
Science, BioWorld MedTech RSS Feed RSS

BioWorld MedTech's Neurology Extra

Nov. 4, 2019
By Liz Hollis and Anette Breindl
Keeping you up to date on recent developments in neurology.
Read More

BioWorld MedTech's Diagnostics Extra

Nov. 1, 2019
By Holland Johnson
Keeping you up to date on recent developments in diagnostics.
Read More

Small molecules clear mutant Huntingtin protein

Nov. 1, 2019
By John Fox
A Chinese study has identified small-molecule compounds that can selectively reduce levels of the mutant Huntingtin (HTT) protein involved in the pathogenesis of Huntington's disease (HD), and possibly other neurodegenerative diseases involving mutant protein accumulation.
Read More

BioWorld MedTech's Orthopedics Extra

Oct. 31, 2019
By Holland Johnson
Keeping you up to date on recent developments in orthopedics.
Read More

BioWorld MedTech's Oncology Extra

Oct. 30, 2019
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology.
Read More

BioWorld MedTech's Cardiology Extra

Oct. 29, 2019
By Liz Hollis
Keeping you up to date on recent developments in cardiology.
Read More

BioWorld MedTech's Neurology Extra

Oct. 28, 2019
By Andrea Applegate
Keeping you up to date on recent developments in neurology.
Read More
Less is more

Rightsizing brain activity increases lifespan, but REST is not all good

Oct. 28, 2019
By Anette Breindl
Two very different roles were reported for the protein REST last week. In adults, REST activation appeared to extend lifespan by reducing overall brain activity. Principal investigator Bruce Yankner, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for the Biology of Aging, told BioWorld MedTech that in postmortem brain samples of individuals who had had no cognitive impairments at the time of their death, his team found "a correlation between down-regulation of excitation and extended longevity."
Read More

BioWorld MedTech's Diagnostics Extra

Oct. 25, 2019
By Meg Bryant and Anette Breindl
Keeping you up to date on recent developments in diagnostics.
Read More

BioWorld MedTech's Orthopedics Extra

Oct. 24, 2019
By Holland Johnson
Keeping you up to date on recent developments in orthopedics.
Read More
Previous 1 2 … 61 62 63 64 65 66 67 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing